Analytical Data
-
基因名
CLEC12A
- Application
-
别名
CLEC12A；CLL1；DCAL2；MICL；C-type lectin domain family 12 member A
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5QGZ9
-
表达区间
1-265aa
-
氨基酸序列
MSEEVTYADLQFQNSSEMEKIPEIGKFGEKAPPAPSHVWRPAALFLTLLCLLLLIGLGVLASMFHVTLKIEMKKMNKLQNISEELQRNISLQLMSNMNISNKIRNLSTTLQTIATKLCRELYSKEQEHKCKPCPRRWIWHKDSCYFLSDDVQTWQESKMACAAQNASLLKINNKNALEFIKSQSRSYDYWLGLSPEEDSTRGMRVDNIINSSAWVIRNAPDLNNMYCGYINRLYVQYYHCTYKKRMICEKMANPVQLGSTYFREA
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC12A, or C-type lectin domain family 12 member A, is a type of receptor that plays a significant role in immune responses, particularly in myeloid cells such as monocytes and dendritic cells. Research has indicated that CLEC12A is involved in various immune functions, including the regulation of inflammation and the recognition of pathogens. Its expression is often upregulated in various disease conditions, such as cancer and autoimmune disorders, making it a critical biomarker for disease progression and a potential target for therapeutic interventions. Recent studies have focused on generating recombinant CLEC12A proteins to better understand its structural and functional properties, elucidate its interaction with ligands, and explore its potential as a target for drug development. By creating and characterizing these recombinant proteins, researchers aim to uncover the mechanisms by which CLEC12A contributes to immune modulation and host defense, paving the way for innovative treatments that harness the body’s immune capabilities. Furthermore, the application of recombinant CLEC12A in vaccine development and immune therapies highlights its importance in advancing our understanding of immune responses and improving patient outcomes in various diseases.
